Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:19 AM
Ignite Modification Date:
2025-12-26 @ 1:57 AM
NCT ID:
NCT00601705
Group ID:
EG000
Title:
Epirubicin, Oxaliplatin and Fluorouracil
Description:
cisplatin: 20 mg/m2/day IV continuous infusion over 24 hours for 96 hours.
epirubicin hydrochloride: 50 mg/m2 IV bolus
fluorouracil: 200 mg/m2/day continuous infusion for all 9 weeks, beginning on day 1.
oxaliplatin: 130 mg/m2 IV infusion over 2 hours
adjuvant therapy: At 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given. Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
neoadjuvant therapy: Three weeks after discontinuing the fluorouracil patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for app
Deaths Number Affected:
41
Deaths Number At Risk:
None
Serious Number Affected:
24
Serious Number At Risk:
60
Other Number Affected:
60
Other Number At Risk:
60
Study:
NCT00601705
Results Section:
NCT00601705
Adverse Events Module:
NCT00601705